These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16269594)

  • 1. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.
    Conti PS; White C; Pieslor P; Molina A; Aussie J; Foster P
    J Nucl Med; 2005 Nov; 46(11):1812-8. PubMed ID: 16269594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment for the image interpretation of 111In-ibritumomab tiuxetan in the phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma].
    Oriuchi N; Koizumi K; Koizumi M; Terui S; Yamaura H; Imai Y; Kaneta T; Nawano S; Kubo A; Nishimura T; Kinuya S; Tobinai K; Endo K
    Kaku Igaku; 2008 May; 45(2):99-113. PubMed ID: 19591405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
    Grillo-López AJ
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Spies SM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):10-3. PubMed ID: 14762739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.
    Otte A
    Hell J Nucl Med; 2008; 11(1):12-5. PubMed ID: 18392220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Zimmer AM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
    Gregory SA
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):17-22. PubMed ID: 14710399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Gordon LI
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Borghaei H; Schilder RJ
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):4-9. PubMed ID: 14762738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
    Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
    Esmaeli B; McLaughlin P; Pro B; Samaniego F; Gayed I; Hagemeister F; Romaguera J; Cabanillas F; Neelapu SS; Banay R; Fayad L; Wayne Saville M; Kwak LW
    Ann Oncol; 2009 Apr; 20(4):709-14. PubMed ID: 19150940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
    Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
    Perk LR; Visser OJ; Stigter-van Walsum M; Vosjan MJ; Visser GW; Zijlstra JM; Huijgens PC; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1337-45. PubMed ID: 16832633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
    Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.
    Fisher DR; Shen S; Meredith RF
    J Nucl Med; 2009 Apr; 50(4):644-52. PubMed ID: 19289440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future directions in radioimmunotherapy for B-cell lymphoma.
    Horning SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.